CBR

EN

Our innovations

Pioneering procedure in Tychy

Tychy, 10 October 2014

Physicians from the Centre for Cardiovascular Research and Development American Heart of Poland conducted the first procedure in Europe within the scope of renal denervation with the use of modern Peregrine System. It ensures renal denervation through chemical neurolysis. As emphasizes Krzysztof Milewski, MD, PhD, from the CCRD AHP, this procedure is undoubtedly less severe for the patients than previous methods of renal denervation. The procedure is shorter and it does not require administration of strong analgesics.

The innovative procedure of renal denervation was performed at American Heart of Poland in Tychy. The patient was 56-year-old female, resident of Silesia, who has been fighting against hypertension for more than 10 years. The woman belongs to the group of people who are resistant to standard treatment of hypertension based on pharmacological methods and chance of lifestyle and diet. This was the reason why she was qualified for the renal denervation procedure conducted with the use of the new generation system. The procedure was successful. In a few months, we will see whether the method we used is effective, said Krzysztof Milewski, MD, PhD. The patient has been already discharged from the hospital.
Renal denervation procedures involve destruction of nerves surrounding arteries that supply kidneys with the blood. These nerves play a key role in blood pressure regulation.
Among previously available methods of denervation, the most commonly used procedures involved application of electrical stimulation. Unfortunately, these methods have many limitations and they are very painful, and that is a reason for searching for better solutions. One of them is Peregrine System that provides renal denervation through chemical neurolysis, i.e. local administration of the agent damaging nerves into the artery wall through a special catheter equipped with a micro-needle conducting electric impulses. This system is tested by physicians from the American Heart of Poland.

The American Heart of Poland is globally recognized in treatment of cardiovascular diseases and in introducing modern technologies at the highest global level, emphasizes Professor Paweł Buszman, AHP Group Chief Executive Officer.

Arterial hypertension is a very dangerous disease. Pressure jumps may lead to stroke, myocardial infarction and renal damage, reminds Krzysztof Milewski, MD, PhD. Each patient suffering from this disease is forced to take many antihypertensive drugs with many side effects, he adds.

Peregrine catheter provided by an American company Ablative Solutions has not been approved for use in Europe yet. This is the first study of this type conducted in the clinical practice. Advantage of this method is the fact that the procedure is completely painless for the patients and it lasts only a few minutes, says Krzysztof Milewski, MD, PhD, AHP General Director. Peregrine System is going to be tested in 2 centers in Poland. It is assumed that in the first stage, 20 patients will be enrolled.


Efficacy of Peregrine system has already been verified by physicians – at the CCRD AHP in Kostkowice – on an animal model. As emphasized Piotr Buszman, MD, PhD, AHP Preclinical Reserach Director, Procedures were successful. Not any problems did we have with their correct performance, and they have also caused no adverse events.

Arterial hypertension is a significant health and economic problem. Patients with hypertension have significantly increased risk of occurrence of such major adverse cardiac event as: myocardial infarctions, strokes and renal failure. It is estimated that nearly 30% of the Polish population demonstrate problems with hypertension. Among a group of patients with diagnosed hypertension, nearly 15% are patients with the so-called resistant hypertension, which means inability to lower blood pressure to the desired level despite of using standard pharmacological therapy, diet and lifestyle change.

The CCRD AHP is the only one private center in Poland that conducts preclinical and clinical studies within the scope of cardiovascular diseases. The facility has modern treatment rooms and operating rooms, including one of the cutting-edge hybrid room, where cardiology procedures and cardiac surgeries are performed.

Przeczytaj także:

Do góry